Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

Employees

Sector

Biotechnology & Medical Research

More about the company

09-25	Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
09-09	Incannex Healthcare Commences Patient Dosing in DReAMzz Phase 2 Study Of IHL-42X and Reports Clinical Progress	CI

Market Cap	59.3M 41.65M 36.55M 34.52M 31.46M 58.88M 3.99B 413M 160M 2.04B 156M 153M 6.55B	P/E 2027 *	-2.29x	P/E 2028 *	-1.81x
Enterprise Value	59.3M 41.65M 36.55M 34.52M 31.46M 58.88M 3.99B 413M 160M 2.04B 156M 153M 6.55B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	87.66%	Yield 2027 *	-	Yield 2028 *	-

09-25	Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2026	CI
09-09	Incannex Healthcare Commences Patient Dosing in DReAMzz Phase 2 Study Of IHL-42X and Reports Clinical Progress	CI
08-25	Incannex Healthcare Doses First Patient In DReAMzz Phase 2 Study Of IHL-42X	CI
08-11	Incannex Healthcare Receives Additional AUD 5.1 Million R&D Tax Incentive Refund, Completing More Than AUD 11.2 Million In Non-Dilutive Capital Received In 2026	CI
07-23	Incannex Healthcare Inc. Commences Participant Screening In Dreamzz Phase 2 Study Of IHL-42X For Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	CI
06-25	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea	MT
05-15	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.	CI
05-15	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-14	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea	RE
05-14	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea	CI
04-22	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints	CI
03-27	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position	RE

09-09	Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position	AQ
08-25	Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X	AQ
08-11	Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026	AQ
07-23	Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea	AQ
06-25	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea	AQ

Manager	Title	Age	Since
Joel Latham CEO	Chief Executive Officer	37	31/12/2015
Joseph Swan DFI	Director of Finance/CFO	35	28/02/2024
Luigi Barbato CTO	Chief Tech/Sci/R&D Officer	63	20/10/2024

Mount Magnet South Ltd Share Price Australian S.E.

Stocks

AU000000MUM1

Biotechnology & Medical Research

Valuation: Mount Magnet South Ltd

Latest news: Mount Magnet South Ltd

Analysts' recommendations: Mount Magnet South Ltd

Press Releases: Mount Magnet South Ltd

Managers and Directors: Mount Magnet South Ltd

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Troy Valentine CHM	Chairman	52	31/10/2023
Peter Widdows BRD	Director/Board Member	60	31/10/2023
Joel Latham BRD	Director/Board Member	37	31/12/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+51.24%	+99.26%	72.26B
ARGENX SE	+1.25%	-3.01%	+40.12%	+77.12%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+32.50%	+21.28%	27.73B
INSMED INCORPORATED	-3.06%	-1.81%	-13.10%	+357.06%	25.74B
BIONTECH SE	-0.75%	+2.56%	+0.45%	-4.46%	24.75B
GENMAB A/S	+0.40%	+0.75%	+22.91%	-9.68%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+146.86%	+314.52%	15.06B
EXELIXIS, INC.	+0.36%	-0.34%	+50.32%	+166.42%	14.42B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-8.07%	+499.10%	14.23B
Average	-0.50%	+0.44%	+35.92%	+168.96%	30.57B
Weighted average by Cap.	-0.77%	+0.31%	+36.31%	+129.11%

	2027 *	2028 *
Net sales	-	-
Net income	-24.89M -17.48M -15.34M -14.48M -13.2M -24.71M -1.68B -173M -67.13M -856M -65.62M -64.2M -2.75B	-30.9M -21.7M -19.04M -17.99M -16.39M -30.68M -2.08B -215M -83.36M -1.06B -81.48M -79.72M -3.42B
Net Debt	-	-

End-of-day quote Australian S.E.
- ^AUD	-